Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review

Classical Hodgkin lymphoma (cHL) has achieved high cure rates as a result of recent advancements in treatment. However, recurring or relapsed illness still poses a therapeutic challenge. Immune checkpoint inhibitor pembrolizumab, which targets PD-1, is now being commonly used as part of immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Md Fahad, Kharel, Manish, Akter, Mahfuza, Parajuli, Bibek, Yadav, Indresh, Mandal, Nitesh, Mandal, Anjali, Aziz, Syed Nurul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602819/
https://www.ncbi.nlm.nih.gov/pubmed/37900494
http://dx.doi.org/10.7759/cureus.46032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602819/
https://www.ncbi.nlm.nih.gov/pubmed/37900494
http://dx.doi.org/10.7759/cureus.46032

Ejemplares similares